The certification approves the manufacturing and processing line and high quality system of SK bioscience’s Andong plant, which produces Covid-19 vaccines developed by AstraZeneca Plc and Novavax Inc. It should allow SK to export vaccines to the European markets.
SK bioscience can be trying to receive the Present Good Manufacturing Apply laws enforced by the U.S. Food and Drug Administration, it stated in a press release.
It has been supplying the AstraZeneca vaccine it has produced to the home market and the worldwide vaccine sharing facility COVAX.
SK bioscience additionally has a license settlement with Novavax to supply 40 million Covid-19 vaccine doses for South Korea in addition to a contract improvement and manufacturing deal for international provide.
“The worldwide vaccine demand is anticipated to surge explosively pushed by the pandemic … Primarily based on the globally recognised high-level know-how, we’ll speed up our enterprise enlargement,” SK bioscience CEO, Ahn Jae-yong stated in a press release.
Shares in SK bioscience jumped as a lot as 8.6%, outperforming a 0.1% drop within the broader market.